Abstract

Concerns of a tumorigenic risk of styrene (ST) originate from the findings that styrene (ST) is metabolized to the genotoxic intermediate styrene-7,8-oxide (SO). Therefore, it was hypothesized that results of animal long-term studies with ST and SO together with the SO tissue burden are sufficient for conducting a ‘worst case’ estimate of the tumorigenic risk of ST. On this basis we predicted the excess human lifetime risk for lung tumors ( p EXL) and the highest possible risk for other systemic tumors ( p HPS) resulting from daily intake of ST via food and ambient air. As measures for p EXL the mean lifetime concentration of SO in the transitional zone of the lung and for p HPS the mean lifetime concentration of SO in blood were calculated using a physiological toxicokinetic model. For a daily oral intake of 12 μg ST, p EXL was obtained to be between 5×10 −9 and 2×10 −8 and p HPS to be between 7×10 −9 and 2×10 −8. Lifetime risks calculated for continuous exposure to 3 μg/m 3 ST in ambient air were between 8×10 −7 and 3×10 −6 ( p EXL) and between 2×10 −8 and 4×10 −8 ( p HPS). Although these values indicate very low risks, the actual risks are expected to be even by far smaller. This is discussed in detail for lung tumorigenesis.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.